Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Down 7.0% in November
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 18,130,000 shares, a drop of 7.0% from the October 31st total of 19,500,000 shares. Based on an average daily volume of 5,540,000 shares, the short-interest ratio is presently 3.3 days.
Gilead Sciences Trading Up 0.9 %
Shares of GILD stock traded up $0.69 during mid-day trading on Monday, hitting $78.34. The company’s stock had a trading volume of 8,194,576 shares, compared to its average volume of 5,775,686. The company’s fifty day simple moving average is $76.79 and its 200-day simple moving average is $77.05. Gilead Sciences has a 52 week low of $72.87 and a 52 week high of $89.74. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.20 and a current ratio of 1.34. The company has a market cap of $97.61 billion, a PE ratio of 16.81, a P/E/G ratio of 1.02 and a beta of 0.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.38. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. The firm had revenue of $7.05 billion during the quarter, compared to analyst estimates of $6.81 billion. During the same period last year, the company posted $1.90 EPS. The business’s quarterly revenue was up .1% on a year-over-year basis. As a group, equities research analysts expect that Gilead Sciences will post 6.75 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 64.38%.
Insider Transactions at Gilead Sciences
In related news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total transaction of $115,561.99. Following the sale, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total transaction of $115,561.99. Following the sale, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the sale, the chief financial officer now directly owns 104,003 shares in the company, valued at approximately $8,320,240. The disclosure for this sale can be found here. 0.21% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. PCA Investment Advisory Services Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $25,000. Tompkins Financial Corp raised its stake in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the period. OFI Invest Asset Management acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $26,000. Union Savings Bank acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $29,000. Finally, Sanctuary Wealth Management L.L.C. bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $30,000. 82.33% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
GILD has been the topic of a number of research analyst reports. StockNews.com initiated coverage on Gilead Sciences in a report on Thursday, October 5th. They issued a “strong-buy” rating on the stock. HSBC initiated coverage on Gilead Sciences in a report on Wednesday, September 6th. They issued a “reduce” rating and a $71.00 target price on the stock. Bank of America raised Gilead Sciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $88.00 to $95.00 in a report on Friday, September 8th. Royal Bank of Canada cut their price objective on Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 14th. Finally, UBS Group cut their price objective on Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $87.24.
Get Our Latest Stock Analysis on GILD
About Gilead Sciences (Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Gilead Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Gilead Sciences wasn’t on the list.
While Gilead Sciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.
Original: MarketBeat News Feed: Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Down 7.0% in November